Ablynx upbeat on 1st-half results but investors unsure

25 August 2016

Belgian drugmaker Ablynx (Euronext Brussels: ABLX) has posted 2016 half-yearly financial results showing its revenue and grant income rose by 39% compared to 2015’s first six months.

The company generated 53.1 million euros ($60 million) in revenue in the period ending June 30, and 391,000 euros in grants, and the combined 53.5 million euros figure is well above the 38.4 million total from a year ago.

This was mainly driven by milestone payments and increased recognized income from upfront payments received from Ablynx’ partners, including privately-owned German firm Boehringer Ingelheim, US pharma giant Merck & Co (NYSE: MRK) and Danish diabetes company Novo Nordisk (NOV: N).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK